A PEG hydrogel sealant (PleuraSeal TM ) is used as an adjunct to standard closure of pleural air leaks during lung resection surgery and has demonstrated shorter hospitalizations (1.7 days fewer) and more rapid removal of chest tubes in clinical studies when compared with standard of care (e.g. staples and sutures alone). Our study was designed to estimate the potential cost offsets for using PleuraSeal TM compared with standard of care in 100 hypothetical patients from a UK hospital who had an air leak after lung resection surgery using the cost offset from shorter hospital stays balanced against the cost for PleuraSeal TM . METHODS: We assumed the cost for PleuraSeal TM to be £360 per treatment applied to all 100 hypothetical patients compared with no added cost for standard of care. We then balanced the added cost for PleuraSeal TM with the reduction in number of hospital days and subsequent costs compared with standard of care (£280/day @1.7 days fewer per patient) and calculated the potential cost offsets for PleuraSeal TM . RESULTS: A hospital with 100 lung resection surgery patients with air leaks can expect to save £11,588, or approximately £17 per patient when compared to standard of care as patients who had air leaks stayed in hospital an average of 1.7 days longer than those without air leaks. CONCLUSIONS: The cost for PleuraSeal TM is completely offset by the shorter length of hospital stay compared with standard of care. PleuraSeal TM is a compelling option for hospitals who perform lung resection surgeries as the cost of the treatment is completely offset by the reduction in air leaks and subsequent hospital stay. OBJECTIVES: There is inconclusive evidence on the advantages of branded levalbuterol over generic albuterol. This study is the first to examine the use and spending of these two short-acting beta agonists in a nationally representative sample of Medicare patients with COPD enrolled in Medicare Part D. The study also examines patient characteristics associated with levalbuterol use and compares the use of other Medicare Parts B and D covered COPD medications among albuterol and levalbuterol users. METHODS: Data were obtained from the 2005-2006 5% Medicare files linked to the 2006 Medicare Part D files. The sample consisted of all fee-for-service beneficiaries with COPD enrolled in stand-alone Part D plans in 2006. Patient characteristics and other COPD medication use were compared across albuterol-only users, levalbuterol-only users, and users of both medications. Multinomial logistic regressions identified the independent factors associated with levalbuterol use. RESULTS: There were 5.5 times more albuterol users than levalbuterol users; yet total spending on levalbuterol was $169 million whereas on albuterol was $50 million in 2006. Levalbuterol-only users were more likely to be older, sicker, and reside in the South than albuterol-only users. Part B covered nebulizer formulations were more frequently used among levalbuterolonly users whereas albuterol-only users were more likely to use inhalers under Part D. CONCLUSIONS: Our findings on the striking differences between levalbuterol and albuterol users in terms of spending, patient characteristics, geographic region, and drug formulation/device type call for further investigations into these issues as well as comparative effectiveness and cost-effectiveness studies of these agents.
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COST-UTILITY ANALYSIS OF TIOTROPIUM, MEDICINE FOR CHRONIC OBSTRACTIVE PULMONARY DISEASES (COPD) , IN JAPAN
Igarashi A 1 , Kato Y 1 , Makita H 2 , Fukuda T 1 , Nishimura M 2 , Tsutani K 1 1 Tokyo University, Tokyo, Japan, 2 Hokkaido University School of Medicine, Sapporo, Japan OBJECTIVES: To assess cost-effectiveness of tiotropium (Spiriva®), long-acting anticholinergic agent for Chronic Obstructive Pulmonary Diseases (COPD), and ipratropium in Japan. METHODS: A Markov model was constructed to analyze costs and Quality-Adjusted Life Years (QALYs) from the health care payers'perspective. Prior to construct the model, we assessed utility scores (disease-specific SGRQ scores and EQ-5D scores) and out-patient medicinal costs among COPD patients visiting Hokkaido University Hospital, classified by COPD severity. Medical costs other than medicinal costs (diagnosis, hospitalization, exacerbation, etc) were calculated from health insurance claim data in Hokkaido University Hospital. We captured costs and outcomes for 5 years. In the Markov model, 1 month was set as one cycle. Both costs and utility were discounted at 3% annually. We set the numbers of exacerbations and QALYs as outcomes. RESULTS: Both of SGRQ scores and EQ-5D scores were significantly influenced by COPD severity. Average EQ-5D scores for severe/very severe and moderate patients were 0.68,and 0.87, respectively. Average SGRQ scores for severe/ very severe and moderate patients were 26.1 and 46.1, respectively. COPD severity also significantly influenced out-patient medicinal costs. Per diem out-patient medicinal costs of severe/very severe and moderate patients were JPY338 and 135, respectively (USD1 = JPY92) . As the results of Markov-model analysis, tiotropium would save JPY966,000 or USD10,500 (JPY2,604,000 vs. JPY3,570,000) , reduce the numbers of exacerbations (0.46 vs. 0.99) and increase 0.258QALY (3.300 vs. 3.042), compared to ipratropium.Various sensitivity analysis, both one-way and probabilistic one, showed the robustness of the results. From the budget impact analysis, if whole 220,000 COPD patient (based on Patient Survey 2005), use tiotropium instead of ipratropium, we would save JPY215 bil or USD2.34bil. CONCLUSIONS: Spiriva® for COPD patients in Japan, is thought to be cost-effective and would save health care budget.
PRS27
COST-UTILITY ANALYSIS OF ANTI-SMOKING TREATMENTS
Brault C 1 , Rinfret S 2 , Lachaine J 1 1 University of Montreal, Montreal, QC, Canada, 2 Quebec Heart and Lung Institute, Quebec, QC, Canada OBJECTIVES: Approximately 4.5 million Canadians, or 18.6% of the total population, smoke. Although the prevalence of smoking has shown a significantly decreasing trend, nicotine dependence remains a major public health issue. A number of pharmacological treatments are available to help smokers quit such as nicotine replacement therapies, bupropion and varenicline. The objective of this study was to evaluate the incremental cost-utility ratio of pharmacological anti-smoking treatments. METHODS: A Markov model based on the Benesco Simulation model (the Benefits of Smoking Cessation on Outcomes) was developed to determine the costs and QALYs associated with the nicotine replacement therapies, bupropion and varenicline. This cost-utility analysis was performed over a lifetime horizon and from a health care system perspective. The model considers the health status of smokers, recent non-smokers and longterm non-smokers; the adverse health outcomes of smoking (asthma, chronic obstructive pulmonary disease [COPD], coronary heart disease, stroke and lung cancer); and deaths from all causes and from smoking. The model also considers smoking cessation probabilities associated with anti-smoking treatments, probabilities of resuming, probabilities of complications attributable to smoking, and probabilities of death. The costs considered are the costs of anti-smoking treatments according to recommended doses and amounts reimbursed by the Régie de l'assurance maladie du Québec. RESULTS: Nicotine patches, with higher costs and less QALYs, are dominated by both bupropion and varenicline. Nicotine gum is also dominated by bupropion. Varenicline is the most effective of the anti-smoking treatments studied, albeit more costly than nicotine gum and bupropion. The incremental cost-utility ratios for varenicline versus nicotine gum and bupropion are respectively $825 and $1,235 per QALY. CONCLUSIONS: Results show that varenicline is the most effective option of the currently available pharmacological anti-smoking treatments, with a very acceptable cost-utility ratio.
PRS28
COST-UTILITY ANALYSES OF DISEASE-MODIFYING THERAPIES FOR PATIENTS WITH RELAPSE-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATE
Yang M, Tseng WW, Sansgiry SS University of Houston, Houston, TX, USA OBJECTIVES: To assess cost effectiveness of Natalizumab, Glatiramer Acetate (GA) and Interferon-β in treating patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) from a United States (US) patient's perspective. METHODS: A 30-year Markov model was developed with patients transitioning through health states based on the Kurtzke Expanded Disability Status Scale (EDSS). Patient health status was defined as mild, moderate, or severe when their EDSS score was 0.0-3.5, 4.0-6.0, 6.5-9.5, respectively. The model was parameterized with data from an extensive literature review and was adjusted where necessary to 2008 values. Transition probabilities included patients initial distribution based on EDSS score, relapse rate, mortality rate, and progression rate. The total cost included direct (inpatient and outpatient admissions, office visits to physicians, examinations, medication, medical devices, alterations to the care, and informal care from family) and indirect costs (productivity losses, and early retirement). The utility considered was Quality Adjusted Life-Year (QALY). Sensitivity analyses were conducted on all the transition probabilities at a range of ± 25% to check the robustness of the result. RESULTS: Based on the result of the 30 year Markov Model, patients treated with Natalizumab spend $1,104,773 to gain 10.47 QALYs, while patients treated with Interferon-β spend $880,199 to obtain 9.88 QALYs and for those patients treated with GA have to pay $907,854 to yield 7.07 QALYs, which means patients treated with Natalizumab, Interferon-β or GA have to spend $105,517, $89,088, $128,409 respectively to gain one QALY. The model suggests that Interferon-β is the most cost-effective DMT agent, with an ICER of $380,634 per QALY compared with Natalizumab. Compared with GA, the ICER for Interferon-β per QALY was $9,841. Sensitivity analysis showed that the results were robust to changes in all parameters. CONCLUSIONS: In our study, Interferon-β proved to be more cost effective than both Natalizumab and GA for RRMS patients.
PRS29 SMOKING AND WORKPLACE CONSEQUENCES: EVALUATION IN FRANCE
Dautzenberg B 1 , Osman J 1 , Pibourdin JM 2 , Charles T 3 1 OFT, PARIS, France, 2 Pierre Fabre, Boulogne cedex, France, 3 CREES PFSA, Boulogne, France OBJECTIVES: Tobacco is the primary cause of preventable death in France (66,000 deaths/Y). Places of work and business are no exception.The objective of this study is to gain a better understanding of smoking and its consequences at work, thereby permitting new data to be obtained which will encourage businesses to take smoking into account. METHODS: In June 2009, the CSASantéInstitute composed a representative sample of the active French population according to the quota method. A total of 1950 people were interviewed. RESULTS: Of the total active population, there is no significant difference according to business size relative to the prevalence of smokers. The relationship between smoking and the number of breaks is linear (1 break for 2.5 cigarettes smoked/day). Smokers are subject to even more criticism (because of their break) by their colleagues and their hierarchy if they are heavy smokers. Smokers of more than 1 pack a day tend to be accompanied for their breaks. Smokers have more disrupted
